Your browser doesn't support javascript.
loading
Healthcare Utilization and Costs in Children Receiving Home Mechanical Ventilation in Ontario: A 14-Year Cohort Study.
Amin, Reshma; Verma, Rahul; Bai, Yu Qing; Guttmann, Astrid; Cohen, Eyal; Gershon, Andrea; Katz, Sherri Lynne; Lim, Audrey; Rose, Louise.
Afiliação
  • Amin R; The Hospital for Sick Children, Department of Paediatrics, Toronto, Ontario, Canada; reshma.amin@sickkids.ca.
  • Verma R; The Hospital for Sick Children, Pediatric Respiratory Medicine, Toronto, Ontario, Canada.
  • Bai YQ; University of Toronto, Toronto, Ontario, Canada.
  • Guttmann A; The Hospital for Sick Children, Pediatrics, Toronto, Ontario, Canada.
  • Cohen E; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
  • Gershon A; The Hospital for Sick Children, Pediatrics, Toronto, Ontario, Canada.
  • Katz SL; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
  • Lim A; Sunnybrook Health Sciences Centre, Department of Respirology & Clinical Immunology, Toronto, Ontario, Canada.
  • Rose L; Children's Hospital of Eastern Ontario, Respiratory Medicine, Ottawa, Ontario, Canada.
Ann Am Thorac Soc ; 2024 Jul 03.
Article em En | MEDLINE | ID: mdl-38959407
ABSTRACT
RATIONALE Home mechanical ventilation (HMV) is an advanced medical therapy offered to children with medical complexity. Despite the growing pediatric HMV population in North America, there are limited studies describing healthcare utilization and predictors of highest costs using robust health administrative data.

OBJECTIVES:

To describe patterns of healthcare utilization and costs in children receiving HMV over a 14-year period in Ontario, Canada.

METHODS:

We conducted a retrospective population-based cohort study (April 1, 2003 to March 31, 2017) of children aged 0-18 years receiving HMV via invasive mechanical ventilation (IMV) or non-invasive ventilation (NIV). Paired t-tests compared healthcare system utilization and costs two years before and two years after HMV approval. We developed linear models to analyze variables associated with children in the top quartile of health service utilization and costs.

RESULTS:

We identified 835 children receiving HMV. In the two years after HMV approval compared to the 2 years prior, children had decreased hospitalization days (median 9 (IQR 3-30) versus 29 (6-99), p<0.0001) and ICU admission days (6.6 (1.9-18.0) versus 17.1 (3.3-70.9), p<0.0001) but had increased homecare service approvals (195 (24-522) versus 40 (12-225), p<0.0001) and outpatient Pulmonology visits (3 (1-4) versus 2 (1-3), p<0.0001). Total healthcare costs were higher in the two years after HMV approval (mean $164,892 (SD $214,187) versus $128,941 ($194,199), p<0.0001). However, all-cause hospital admission costs were reduced ($66,546 ($142,401) versus $81,578 ($164,672), p<0.0001). Highest total 2-year costs were associated with IMV (OR 3.45, 95% CI 2.24-5.31; reference NIV), number of medical devices at home (OR 1.63, 95% CI 1.35-1.96; reference no technology), and increased healthcare costs in the year prior to HMV initiation (OR 2.23, 95% CI 1.84-2.69).

CONCLUSIONS:

Children progressing to the need for HMV represent a worsening in their respiratory status that will undoubtedly increase healthcare utilization and costs. We found that the initiation of HMV in these children can reduce inpatient healthcare utilization and costs but can still increase overall healthcare expenditures, especially in the outpatient setting.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Am Thorac Soc Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Am Thorac Soc Ano de publicação: 2024 Tipo de documento: Article